Absent benefit of accelerated concomitant chemoradiotherapy

We read with interest the report of the GORTEC 99-02 randomised phase 3 trial¹ in locally advanced head and neck carcinoma that compared altered fractionation schedules with or without chemotherapy conventional concomitant chemoradiotherapy. The idea behind accelerated radiotherapy is that a shortened overall treatment time will reduce tumour-cell repopulation during treatment.2 A meta-analysis showed a small survival benefit of 3.4% at 5 years for altered fractionation radiotherapy in the absence of chemotherapy.³ Before the GORTEC 99-02 and RTOG 0219 studies,4 whether the combination of acceleration and concomitant chemotherapy is beneficial compared with conventionally fractionated chemoradiotherapy was uncertain.

The GORTEC study¹ compared conventionally fractionated chemoradiotherapy (70 Gy in 35 fractions over 7 weeks plus three cycles of 4-day concomitant carboplatin-fluorouracil) with accelerated radiochemotherapy (70 Gy in 6 weeks plus two cycles of 5-day concomitant carboplatinfluorouracil) and very accelerated radiotherapy (64.8 Gy in 3.5 weeks with 1.5 Gy fractions twice daily). The two concomitant chemoradiotherapy groups had equivalent outcomes whereas accelerated radiotherapy was inferior. These results are consistent with the RTOG 0129 study,4 which showed no benefit of an accelerated schedule of 72 Gy in 6 weeks with two cycles of concomitant cisplatin versus a conventional group of 70 Gy in 7 weeks with three cycles of cisplatin. Therefore, accelerated radiotherapy does not seem beneficial when combined with concomitant chemotherapy.

Jean Bourhis and colleagues¹ note that in the GORTEC study the

conventional chemoradiotherapy group received 17% more chemotherapy than did the accelerated radiochemotherapy group, and explain their findings by concluding that "acceleration of radiotherapy cannot fully compensate for a missed dose of chemotherapy". However, an alternative explanation is that use of concomitant chemotherapy minimises tumour-cell repopulation and hence precludes any benefit of radiotherapy acceleration. The explanation is especially important in view of the increasing use of modestly accelerated chemoradiotherapy with-by contrast with the GORTEC study—a reduced total radiotherapy dose.² If this alternative explanation is correct, acceleration would be inadequate to compensate for a reduction in radiotherapy dose.

We note that compliance with the third cycle of chemotherapy in the conventionally fractionated chemoradiotherapy group of the GORTEC study was poor (given to 203 of 279 patients). We would be interested to learn whether there is any correlation between chemotherapy delivery (two or three cycles in the conventional chemoradiotherapy group) and outcome to support the authors' conclusion with regard to the importance of chemotherapy dose intensity and the absent benefit of acceleration.

We declare that we have no conflicts of interest.


*Robin J Prestwich, Mehmet Sen rprestwich@doctors.org.uk

St James's Institute of Oncology, Leeds, UK (RJP, MS)

- Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012; 13: 145-53.
- Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: a review. Crit Rev Oncol Hematol 2010; 73: 111–75.
- Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843-54.

4 Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24–35.

Authors' reply



With regard to the potential correlation between the intensity of chemotherapy and clinical outcome in the conventional chemoradiotherapy group, we noted a non-significant trend towards more distant metastases, decreased progression-free survival, and worse survival with two cycles versus three (table, appendix). However, this analysis should be interpreted with caution because it is potentially biased. We did not decide what number of chemotherapy cycles to give (ie, two vs three) at the beginning of the treatment; rather several factors (eg, toxic effects or performance status impairment) meant that some patients could not receive the third cycle. Thus, unlike randomised trials, the groups defined by the number of cycles received could be unbalanced for



See Online for appendix

HR (95% CI)	р
1.438 (0.997-2.074)	0.0518
1.402 (0.965-2.037)	0.0764
1.521 (0.923-2.508)	0.0998
1.822 (0.999-3.321)	0.0503
	1·438 (0·997-2·074) 1·402 (0·965-2·037) 1·521 (0·923-2·508)

HR and p values were calculated after adjustment for tumour stage, node stage, tumour site, and age. HR=hazard ratio.

Table: Hazard ratios for progression-free and overall survival, locoregional failure, and distant metastases of patients given two chemotherapy cycles (n=55) compared with those given three chemotherapy cycles (n=190) in the conventional chemoradiotherapy group